Sunday, July 12, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitor”

2,878 pharma patents match "inhibitor" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,878
Index total 30,257
Page 50 / 120

Quick answer

This filtered view shows 2,878 pharmaceutical patents matching "inhibitor" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,878 results for “inhibitor” · 30,257 patents in full index Clear search

  1. US 10183942

    JAK kinase inhibitor compounds for treatment of respiratory disease

    Theravance Biopharma R&D IP, LLC · Granted Jan 22, 2019 · Expires Jan 17, 2039

    granted
  2. US 10174018

    Protein kinase inhibitors

    Princeton Drug Discovery, Inc · Granted Jan 8, 2019 · Expires Jan 3, 2039

    granted
  3. US 10173985

    Aminoindazole derivatives as sodium channel inhibitors

    Almirall, S.A. · Granted Jan 8, 2019 · Expires Jan 3, 2039

    granted
  4. US 10172844

    Use of CDK9 inhibitors to reduce cartilage degradation

    The Regents of the University of California · Granted Jan 8, 2019 · Expires Jan 3, 2039

    granted
  5. US 10172789

    Compositions for transdermal delivery of mTOR inhibitors

    PALVELLA THERAPEUTICS, INC. · Granted Jan 8, 2019 · Expires Jan 3, 2039

    granted
  6. US 10172840

    Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof

    VTV THERAPEUTICS LLC · Granted Jan 8, 2019 · Expires Jan 3, 2039

    granted
  7. US 10167292

    Benzodiazepines as bromodomain inhibitors

    Catalyst Therapeutics Pty Ltd. · Granted Jan 1, 2019 · Expires Dec 27, 2038

    granted
  8. US 10167259

    Allosteric inhibitors of proteasome and methods of use thereof

    The Board of Regents of the University of Texas System · Granted Jan 1, 2019 · Expires Dec 27, 2038

    granted
  9. US 10166216

    Substituted triazoles useful as Axl inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Jan 1, 2019 · Expires Dec 27, 2038

    granted
  10. US 10160753

    Indazole compounds as IRAK4 inhibitors

    Aurigene Discovery Technologies Limited · Granted Dec 25, 2018 · Expires Dec 20, 2038

    granted
  11. US 10160760

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Dec 25, 2018 · Expires Dec 20, 2038

    granted
  12. US 10155789

    Substrates and inhibitors of prolyl oligopeptidase and methods of use thereof

    The Board of Regents of the University of Oklahoma · Granted Dec 18, 2018 · Expires Dec 13, 2038

    granted
  13. US 10151756

    Predictive markers for polyamine inhibitor cancer therapies

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Dec 11, 2018 · Expires Dec 6, 2038

    granted
  14. US 10150783

    Heterocyclic ITK inhibitors for treating inflammation and cancer

    Aclaris Therapeutics, Inc. · Granted Dec 11, 2018 · Expires Dec 6, 2038

    granted
  15. US 10144930

    Inhibitors of MYH7B and uses thereof

    MIRAGEN THERAPEUTICS, INC. · Granted Dec 4, 2018 · Expires Nov 29, 2038

    granted
  16. US 10138486

    Inhibitors of DEK protein and related methods

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Nov 27, 2018 · Expires Nov 22, 2038

    granted
  17. US 10137121

    Methods of treating cancer with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Nov 27, 2018 · Expires Nov 22, 2038

    granted
  18. US 10138255

    Piperazine derivatives as HIV protease inhibitors

    MSD R&D (China) Co. Ltd. · Granted Nov 27, 2018 · Expires Nov 22, 2038

    granted
  19. US 10137100

    Administration of serine protease inhibitors to the stomach

    The Regents of the University of California · Granted Nov 27, 2018 · Expires Nov 22, 2038

    granted
  20. US 10130623

    Tyrosine kinase inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Nov 20, 2018 · Expires Nov 15, 2038

    granted
  21. US 10131659

    Iodonium analogs as inhibitors of NADPH oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 20, 2018 · Expires Nov 15, 2038

    granted
  22. US 10132810

    Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase I inhibitor

    Nektar Therapeutics · Granted Nov 20, 2018 · Expires Nov 15, 2038

    granted
  23. US 10130642

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Nov 20, 2018 · Expires Nov 15, 2038

    granted
  24. US 10130618

    Pharmaceutical combinations of dabigatran and proton pump inhibitors

    SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI · Granted Nov 20, 2018 · Expires Nov 15, 2038

    granted